Pfizer will acquire Arixa Pharmaceuticals to advance the development of oral antibiotics

Pfizer's hospital business has now agreed to buy Arixa, the next-generation oral antibiotic company focused on developing next-generation oral antibiotics for drug-resistant Gloria-negative infections, announced yesterday (October 22).
the financial terms of the acquisition have not been disclosed.
Arixa's lead compound, ARX-1796, is an oral drug pregenerant of the new β endamidease inhibitor avibactam, an FDA-approved β-endamidease inhibitor (BLI) in 2015.
as part of Avycaz® products (sold by Pfizer outside the United States under the name Zaficefta® ) to treat a variety of adaptive disorders caused by Gloren's negative bacterial infection through intravenous combination cephalosporine.
based on Arixa's existing patented technology, Avibactam prescient drugs can achieve a 60-80% absorption effect in Phase I clinical trials when the patient is taking the drug, thereby releasing FDA-approved Avibactam molecules in the blood.
, direct oral Avibactam can only achieve about 7% of the blood absorption effect.
As drug resistance increases, common Glone-negative bacterial infections, such as complex urinary tract infections, are becoming a major therapeutic challenge, with more and more patients unable to use oral antibiotics and forced to inject drugs intravenously.
β-endamidease inhibitor combination has become the main means of antimicrobial therapy, and clavulanic acid, approved by the FDA in 1984, is currently the only orally inhibited antibiotic.
, however, Avibactam has a broader inhibition of β-endamidease produced by bacteria by antibiotics such as penicillin, cephalosporin and carbon penicillin than kravitic acid.
Arixa management sees Pfizer as the ideal company to incorporate ARX-1796 into subsequent clinical trials and to advance the development of Arixa's leading asset, ARC-1796, to be approved for use in patients in need.
Arixa is currently committed to being a fully virtual company with no employees, with virtually no administrative costs, all through the CRO model, under the supervision of a group of part-time expert consultants, and the ARX-1796 research and development process is driven by this model.
" Pfizer will develop the ARX-1796, and if approved, Arixa's ARX-1796, in combination with antibiotics such as cephalosporine, could become the first new oral β-endamidease inhibitor-antibiotic combination in 35 years to treat urinary tract and other infections.
source: Arixa Pharmaceuticals Announcs By Pfizer's Hospital Business